Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Medexus Pharmaceuticals Inc ( (TSE:MDP) ) has issued an announcement.
Medexus Pharmaceuticals has successfully completed an agreement with British Columbia’s Provincial Health Services Authority for the public reimbursement of Trecondyv in British Columbia. This milestone marks the first step in Medexus’s efforts to secure public reimbursement for Trecondyv across Canada, enhancing its market potential and accessibility for patients who require this treatment.
More about Medexus Pharmaceuticals Inc
Medexus Pharmaceuticals Inc. operates in the pharmaceutical industry, focusing on developing and commercializing innovative therapies for rare diseases. The company offers a range of products, including Trecondyv, a treosulfan injection used in conditioning treatment for stem cell transplantation in patients with acute myeloid leukemia or myelodysplastic syndromes.
YTD Price Performance: 29.57%
Average Trading Volume: 40,602
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: C$110.2M
Learn more about MDP stock on TipRanks’ Stock Analysis page.
